Education
About Us
Working with TipRanks
Follow Us
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
2696 Analyst Ratings
Currently, no data available
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
2696 Stock 12 Month Forecast
There Are No Analyst Ratings for HK:2696 In The Last 3 Months.
| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
2696 Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Goldman Sachs
HK$100.7
Buy
71.84%
Upside
Initiated
10/30/25
Next-gen IO-ADC to lead pipeline globalization; initiate at 2025 | 9:53PM HKT | Research | Equity We initiate coverage on Buy rating and a risk-adjusted DCF-based 12-month TP of HK$100.70. Henlius Biotech is strategically evolving from an early mover in biosimilar to a global innovative biopharma. The transition is well supported by 1) an expanding pipeline led by key assets HLX43, which emerges as a potential best-in-class pan-tumor PD-L1 ADC poised for global pivotal studies; 2) a global biosimilar franchise to provide meaningful cash flow to drive R&D; and 3) early- proven global capabilities in clinical operations, regulatory affairs and biomanufacturing.
Unknown Analyst
TFI Asset ManagementNot Ranked
TFI Asset Management
HK$120.87
Buy
106.26%
Upside
Reiterated
09/16/25
Unknown Analyst
Citic SecuritiesNot Ranked
Citic Securities
HK$130
Buy
121.84%
Upside
Reiterated
08/28/25
CMB International Securities
HK$61.98→HK$97.75
Buy
66.81%
Upside
Reiterated
08/27/25
Unknown Analyst
CICCNot Ranked
CICC
HK$102.91
Buy
75.61%
Upside
Reiterated
08/26/25
Unknown Analyst
CitiNot Ranked
Citi
HK$95
Buy
62.12%
Upside
Reiterated
08/13/25
Unknown Analyst
SWS ResNot Ranked
SWS Res
HK$71
Buy
21.16%
Upside
Reiterated
06/27/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Goldman Sachs
HK$100.7
Buy
71.84%
Upside
Initiated
10/30/25
Next-gen IO-ADC to lead pipeline globalization; initiate at 2025 | 9:53PM HKT | Research | Equity We initiate coverage on Buy rating and a risk-adjusted DCF-based 12-month TP of HK$100.70. Henlius Biotech is strategically evolving from an early mover in biosimilar to a global innovative biopharma. The transition is well supported by 1) an expanding pipeline led by key assets HLX43, which emerges as a potential best-in-class pan-tumor PD-L1 ADC poised for global pivotal studies; 2) a global biosimilar franchise to provide meaningful cash flow to drive R&D; and 3) early- proven global capabilities in clinical operations, regulatory affairs and biomanufacturing.
Unknown Analyst
TFI Asset ManagementNot Ranked
TFI Asset Management
HK$120.87
Buy
106.26%
Upside
Reiterated
09/16/25
Unknown Analyst
Citic SecuritiesNot Ranked
Citic Securities
HK$130
Buy
121.84%
Upside
Reiterated
08/28/25
CMB International Securities
HK$61.98→HK$97.75
Buy
66.81%
Upside
Reiterated
08/27/25
Unknown Analyst
CICCNot Ranked
CICC
HK$102.91
Buy
75.61%
Upside
Reiterated
08/26/25
Unknown Analyst
CitiNot Ranked
Citi
HK$95
Buy
62.12%
Upside
Reiterated
08/13/25
Unknown Analyst
SWS ResNot Ranked
SWS Res
HK$71
Buy
21.16%
Upside
Reiterated
06/27/25
Best Analysts Covering Shanghai Henlius Biotech, Inc. Class H
3 Months
xxx
Success Rate
5/6 ratings generated profit
Average Return
+27.37%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +27.37% per trade.
1 Year
Success Rate
5/6 ratings generated profit
Average Return
+64.90%
reiterated a buy rating 5 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +64.90% per trade.
2 Years
xxx
Success Rate
5/6 ratings generated profit
Average Return
+266.37%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +266.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
2696 Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Jan 26
Strong Buy
1
1
2
1
1
Buy
12
9
6
3
2
Hold
1
1
15
26
44
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
11
23
30
47
Each month's total comprises the sum of three months' worth of ratings.
2696 Stock Forecast FAQ
What is HK:2696’s average 12-month price target, according to analysts?
Currently, no data Available
What is HK:2696’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HK:2696, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Shanghai Henlius Biotech, Inc. Class H a Buy, Sell or Hold?
Currently, no data Available
What is Shanghai Henlius Biotech, Inc. Class H’s share price target?
Currently, no data Available
What do analysts say about Shanghai Henlius Biotech, Inc. Class H?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of Shanghai Henlius Biotech, Inc. Class H?
To buy shares of HK:2696, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.